A study on a triple inhaler for COPD with hyperinflation
Part of Lungs & breathing clinical trials.
This study tests a triple-combination inhaler (budesonide, glycopyrronium, formoterol) against a placebo inhaler to see how it affects your heart and lungs if you have COPD and over-inflated lungs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a current or former smoker with at least a 10 pack-year smoking history (e.g., smoked 1 pack/day for 10 years).
- You have a confirmed COPD diagnosis with moderate to severe airflow obstruction.
- Your lungs are over-inflated (more than 135% of the expected volume).
- You have had at least one COPD flare-up in the past year or are on ongoing maintenance treatment.
- You do not have asthma, a history of certain heart conditions, or a recent lung infection.
- If you are a woman who can become pregnant, you must use highly effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination inhaler (fluticasone, formoterol, and glycopyrronium) for people with COPD. It aims to see if this triple therapy can improve breathing and quality of life compared to current treatments.
This study looks at how well a triple-combination inhaler called Breztri/Trixeo works for people with moderate to severe COPD. If you have been prescribed this inhaler but haven't started it yet, and you are between 30 and 80 years old, you may be able to join.
This trial tests if inhaled corticosteroids (ICS) work better for COPD patients with different eosinophil levels. You must already be taking two long-acting bronchodilators and have stopped smoking for at least 6 months.
This study looks at how often heart problems or stroke happen in people with COPD after they start a specific “triple therapy” inhaler. It may help doctors understand whether these inhalers change cardiovascular (heart) or cerebrovascular (stroke) risk.
This study tests a triple-combination inhaler (budesonide, glycopyrronium, and formoterol) to see if it can help protect the heart and lungs in people with COPD who also have heart problems or high risk for them.
This trial tests a triple combination inhaler (anti-inflammatory plus two bronchodilators) to see if it can improve lung function in people who are showing early signs of chronic lung damage. It might help if you are a smoker with breathing symptoms and your test shows slightly reduced lung function.
Hear when a new Chronic Obstructive Pulmonary Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.